Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAVER: Rosuvastatin for Venous Event Reduction in VTE
NCT04319627Phase 3Recruiting
- Sponsor
- Ottawa Hospital Research Institute
- Start
- Feb 2021
- Primary completion
- Jan 2028
- Modality
- Orthosteric Ligands
- Countries
- 6
01
Overview
A Phase 3 trial of rosuvastatin in venous thromboembolism (VTE), sponsored by Ottawa Hospital Research Institute. Started Feb 2021; status: recruiting.
02
Drugs
rosuvastatin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT04319627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04319627.